WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007002222) PSMA ANTIBODY-DRUG CONJUGATES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/002222    International Application No.:    PCT/US2006/024182
Publication Date: 04.01.2007 International Filing Date: 20.06.2006
IPC:
A61K 47/48 (2006.01)
Applicants: PSMA DEVELOPMENT COMPANY, LLC [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US) (For All Designated States Except US).
MA, Dangshe [CN/US]; (US) (For US Only).
MADDON, Paul, J. [US/US]; (US) (For US Only).
OLSON, William, C. [US/US]; (US) (For US Only).
DORONINA, Svetlana, O. [RU/US]; (US) (For US Only).
TOKI, Brian, E. [US/US]; (US) (For US Only).
SENTER, Peter, D. [US/US]; (US) (For US Only)
Inventors: MA, Dangshe; (US).
MADDON, Paul, J.; (US).
OLSON, William, C.; (US).
DORONINA, Svetlana, O.; (US).
TOKI, Brian, E.; (US).
SENTER, Peter, D.; (US)
Agent: VATLAND, Janice, A.; WOLF, GREENFIELD & SACKS, P.C, 600 Atlantic Avenue, Boston, MA 02210 (US)
Priority Data:
60/692,399 20.06.2005 US
60/792,360 14.04.2006 US
Title (EN) PSMA ANTIBODY-DRUG CONJUGATES
(FR) CONJUGUES ANTICORPS PSMA-MEDICAMENT
Abstract: front page image
(EN)This invention relates generally to antibody-drag conjugates (ADCs). In particular,the invention relates to ADCs which comprise an antibody or antigen-binding fragmentthereof which binds to prostate-specific membrane antigen (PSMA) and is conjugated tomonomethylauristatin norephedrine or monomethylauristatin phenylalanine. The antibody- drug conjugate has a PC-3™ cell to C4-2 or LNCaP™ cell selectivity of at least 250. Theinvention also relates, in part, to compositions of and methods of using the ADCs. Themethods provided include, for example, methods for treating a PSMA-mediated disease.
(FR)L'invention se rapporte de manière générale à des conjugués anticorps-médicaments (ADC: antibody-drug conjugates), et plus particulièrement à des ADC qui contiennent un anticorps ou un fragment de liaison de l'antigène de celui-ci, qui se lie avec l'antigène de membrane spécifique de la prostate (PSMA), conjugués avec de la monométhylauristatine noréphédrine ou de la monométhylauristatine phénylalanine. Ce conjugué anticorps-médicament présente une sélectivité des cellules PC-3™ pour les cellules C4-2 ou LNCaP™ d'au moins 250. L'invention se rapporte également, en partie, à des compositions de conjugués ADC et à des méthodes d'utilisation de ceux-ci. Les méthodes décrites comprennent par exemple des méthodes permettant de traiter les maladies dans lesquelles l'antigène PSMA agit comme médiateur.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)